By Sean Orr, M.D. | October 14, 2026 | Florida Doctor Magazine
At one o’clock this afternoon, in a ballroom at the JW Marriott Grande Lakes in Orlando, Mayo Clinic’s Charles Bruce opened the Florida Innovation Conference with the chairman’s address. Over the next three days the room will hold executives from Pfizer and Bristol Myers Squibb, the research leadership of Mayo, Cleveland Clinic, Moffitt and AdventHealth, venture investors, the Senate President Pro Tempore, and the House member who wrote the law that now sequences the genomes of Florida newborns. Decisions that will reach your exam room in two to five years are being shaped in that room this week, and the people who will have to carry them out are mostly not there. That is the reason this conference deserves a physician’s attention.
What the Conference Is
BioFlorida is the trade association for the state’s life sciences industry, headquartered in Boynton Beach, and the Florida Innovation Conference is its annual meeting. This is the 29th edition. Last year’s drew about 500 attendees and 80 speakers, according to BioFlorida’s own release from December 2025, and the association expects this year to be larger. The 2026 program runs from the opening session today, October 14, through a closing lunch on Friday, October 16.
The industry the conference represents is not small. BioFlorida’s industry data page, drawing on the TEConomy/BIO state profile, counts 9,481 bioscience establishments in Florida as of 2023, places the state in the top quintile nationally for establishments and bioscience patents, and lists $915.6 million in NIH funding to Florida institutions in fiscal 2023. Florida also hosts roughly 1,735 clinical trials. Those trials need principal investigators and referring physicians, which is the first place a practicing doctor fits into this picture.
The Sessions That Will Reach Your Practice
Most of the agenda is written for founders and investors. Four sessions are written, whether the organizers intended it or not, for physicians.
The first is Thursday morning’s general session on the Sunshine Genetics Act, moderated by Quest Diagnostics’ Gaurav Malik with David Ledbetter of the Florida Institute for Pediatric Rare Diseases and Representative Adam Anderson of Palm Harbor, who sponsored the bill. HB 907 took effect July 1, 2025. It created a five-year pilot that offers parents of Florida newborns whole-genome sequencing at no cost, on an opt-in basis, run through the FSU College of Medicine’s rare disease institute with $3 million for the pilot and $4.5 million for the institute in the 2025-26 state budget. The institute has said the pilot can screen for roughly 7,000 rare conditions, about 600 of which have an actionable treatment, against the roughly 60 conditions on the standard state newborn panel. Every one of those results lands with a pediatrician or family physician who will have to explain it to a parent. The session is where the people who built the program will say how they expect that to work.
The second is the Thursday breakout titled “The Path to Future Cures: Innovation, Access and Policy,” which pairs PhRMA’s Sharon Lamberton with Senate President Pro Tempore Jason Brodeur. A pharmaceutical trade group and a Senate leader discussing drug access policy in an election year is, for anyone who has written a prior authorization appeal this month, a conversation worth hearing in person.
The third is Thursday afternoon’s “Health Systems: Innovative Solutions to Patient Care,” with Bruce moderating and Joseph Iannotti of Cleveland Clinic, Jay Lebsack of Moffitt and Alyssa Tanaka of AdventHealth on the panel. These are the systems that employ a growing share of Florida physicians, and this is where they describe to investors what they intend to buy and deploy. The fourth is Friday morning’s “Driving the Future of MedTech,” with Stryker’s Robert Cohen and AdvaMed’s Kirsten Tullia.
As a fellowship-trained neurologist I will admit a personal interest in Thursday’s lunch session on NeuroAI, but the practical point holds for any specialty. The clinical tools of 2030 are being pitched to capital in 2026, and the pitch is better when a clinician has already asked the obvious question.
Who Is in the Room, and Who Is Not
BioFlorida describes its expected attendees as biotech and pharmaceutical companies, device and digital health firms, health systems, research institutions, investors, economic development organizations, startups, and government and policy leaders. The physicians on the program are there as institutional leaders. That is appropriate for the event. What it means in practice is that the practicing physician, the one who will receive the genomic report, implement the device, enroll the trial patient, and absorb the policy, has no standing seat at the table where these things are introduced.
I do not say this as a complaint against BioFlorida, which has built the one place in the state where the Legislature, the hospital systems, the manufacturers and the capital meet in the same week. I say it because the gap is ours to close. Organized medicine in Florida has learned to show up in Tallahassee during session. It has not yet learned to show up in Orlando in October.
What Florida Physicians Can Do
- If you are within driving distance of Orlando, register for Thursday or Friday. The late pricing is steep, but one day in the Sunshine Genetics session and the health systems panel is worth more than a year of reading about them afterward. Faculty appointments qualify for the academic discount if you confirm the affiliation with BioFlorida by email before you arrive.
- If you care for newborns or children, read the Sunshine Genetics Act and contact the Florida Institute for Pediatric Rare Diseases at FSU about how results are returned, who provides genetic counseling, and whether the pilot is enrolling at hospitals in your area. The law created a Sunshine Genetics Consortium of researchers, geneticists and physicians. Ask how a community pediatrician joins it.
- If you have ever considered serving as a principal investigator, the sponsors and contract research organizations in the Innovation Hall are the people who place Florida’s 1,735 active trials. A single conversation about your patient population is how site selection begins.
- Ask your county medical society and your specialty society whether anyone is attending on behalf of practicing physicians, and if the answer is no, ask why. Representative Anderson and Senator Brodeur will both be in that building this week. They should hear from the physicians downstream of their bills, not only from the trade groups upstream of them.
- If you lead a department or a medical staff, bring the Thursday health systems panel back to your medical executive committee. When a system describes to investors what it plans to deploy, the medical staff should hear the same description before the purchase order is signed.
The Bigger Picture
Florida has decided, at the level of the Governor’s office and the Legislature, to compete as a life sciences state. The newborn sequencing pilot, the money flowing to FSU’s rare disease institute, and the economic development offices from Pasco to Fort Lauderdale on Thursday’s panel are all expressions of the same decision, and that decision will shape the medicine we practice whether or not we participate in it. Physicians who want policy done with them rather than to them have to be present where the policy is drafted, and in October that place is a hotel ballroom in Orlando. The conference is open. The question is whether we show up.
Frequently Asked Questions
When and where is the 2026 BioFlorida Innovation Conference?
The Florida Innovation Conference, powered by BioFlorida, runs October 14 through 16, 2026, at the JW Marriott Orlando, Grande Lakes, 4040 Central Florida Parkway. Sessions begin at 1:00 p.m. on Wednesday and close with the BIOPITCH awards and a grab-and-go lunch around 12:30 p.m. on Friday.
Can a practicing Florida physician attend, and what does it cost?
Yes. Registration is open to anyone. Late pricing is $1,200 for BioFlorida members and $1,450 for non-members, and students and faculty receive $150 off after confirming their affiliation by email to BioFlorida. The hotel room block is full, but the JW Marriott and several nearby hotels may still have rooms.
What is the Sunshine Genetics Act and why does it matter to Florida physicians?
The Sunshine Genetics Act, HB 907, took effect July 1, 2025. It funds a five-year pilot offering Florida newborns opt-in whole-genome sequencing at no cost, run through the Florida Institute for Pediatric Rare Diseases at the FSU College of Medicine, and it creates a consortium of researchers, geneticists and physicians to support it. Pediatricians and family physicians will receive and act on the results, so the program’s design directly affects primary care.
How large is Florida’s life sciences industry?
BioFlorida’s industry data, citing the TEConomy/BIO state profile, counts 9,481 bioscience establishments in Florida in 2023, including 632 pharmaceutical and 1,023 medical device firms, with $915.6 million in NIH funding in fiscal 2023 and about $4.3 billion in bioscience venture investment from 2019 to 2023. Florida ranks in the top quintile of states for bioscience establishments and patents.
What is BIOPITCH?
BIOPITCH is the conference’s pitch competition for seed and early-stage life science companies. Finalists present on Friday morning, October 16, in three categories: Florida Premier, with a $60,000 prize for Florida-headquartered companies; Emerging Florida, with $30,000 for companies from Florida universities, incubators and research institutes; and Future Florida, with $10,000 for companies based outside the state.
Florida Doctor Magazine has no commercial relationship with BioFlorida or the conference. Registration details and pricing are as published by BioFlorida on October 14, 2026, and may change.
This article was drafted with the assistance of AI writing tools, then reviewed, edited, and approved by Dr. Sean C. Orr, M.D., who holds full editorial responsibility for its content. The header illustration was created with AI image tools.
References
- BioFlorida. Florida Innovation Conference 2026: registration, agenda, BIOPITCH and awards. bioflorida.com
- BioFlorida. 2026 Innovation Conference agenda. bioflorida.com
- BioFlorida via PR Newswire. Life Sciences Innovators Convene at BioFlorida’s 28th Annual Innovation Conference (Dec. 1, 2025). prnewswire.com
- BioFlorida. Industry Data (TEConomy/BIO 2024 Florida profile; PhRMA; We Work for Health). bioflorida.com
- Florida State University News. Florida surges to forefront of rare disease research with boost from Sunshine Genetics Act (July 9, 2025). news.fsu.edu
- Florida Phoenix. FSU celebrates rare pediatric disease pilot program signed into law (July 9, 2025). floridaphoenix.com
- Florida House of Representatives. HB 907 (2025), Sunshine Genetics Act. flsenate.gov